A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

Inclusion Criteria:

- Measurable metastatic disease or locally advanced and unresectable disease

- Has histopathologically confirmed gastric or GEJ adenocarcinoma with documented
disease progression after 1-2 prior lines of systemic therapy

- Has histopathologically confirmed nonsquamous or squamous NSCLC with documented
disease progression after 1-3 prior lines of systemic therapy

- Has histopathologically or cytologically confirmed HCC, Child-Pugh Class A, with
documented disease progression during or after discontinuation of sorafenib
therapy, or intolerance of sorafenib therapy, and an α-fetoprotein (AFP) ≥ 1.5x
upper limit of normal

- Availability of tumor tissue for biomarker analysis

- Has an Eastern Cooperative Oncology Group Performance Status of 0 or 1

- Has adequate organ function

Exclusion Criteria:

- Has known brain metastases

- Has a history of prior cancers not included in this study that were either not treated
with curative intent or have been active within the past 5 years

- History of allogeneic organ transplant

- Has active or prior documented autoimmune disease within the past 24 months

- Has human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome
(AIDS)-related illness, or a history of immunodeficiency

- Has active hepatitis B or hepatitis C infection, or co-infection with both hepatitis B
and C virus

- For gastric/GEJ and NSCLC participants, has chronic hepatitis B or hepatitis C
infection. (For HCC participants, those with chronic hepatitis B virus [HBV] infection
with a negative HBV deoxyribonucleic acid [DNA] test and who are on antiviral therapy,
and those with chronic hepatitis C virus [HCV] infection are eligible)

- Has a history of interstitial lung disease, idiopathic pulmonary fibrosis,
pneumoconiosis, non-infections pneumonitis, radiation-induced or drug-induced
pneumonitis

- Has received any previous systemic therapy targeting programmed death (PD) 1 or
PD-ligand 1/2 signaling pathways, and other immune checkpoint inhibitors

- Have received previous systemic therapy with ramucirumab